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Abstract and introduction
Single-use bioreactors are well-established in mammalian cell-based biopharmaceutical productions. However, adoption of 
single-use technologies for microbial/yeast-based production has been slow due to the unique requirements of fermentation 
processes. The typical challenges include supporting high-cell density cultivations, high oxygen transfer capacity, and 
efficient heat removal.
Here, we present the single-use XDR-500 MO stirred-tank fermentor system specifically designed for microbial/yeast 
applications. The performance of the fermentor was evaluated using an E. coli fed-batch process producing a domain 
antibody (dAb) as a model system. The process was originally developed for a lab-scale conventional stainless steel (SS) 
system. This work describes the strategy applied to transfer and scale-up this process to the single-use bioreactor (SUB) 
without the need for extensive re-optimization due to technology change.  Moreover, process economy of dAb production 
based on single-use and conventional technology was compared in silico. 
Cell densities and dAb expression levels similar to the lab-scale conventional bioreactor were achieved in XDR-500 MO, 
confirming feasibility of single-use technology even in microbial processes. 
Materials and methods
Fed-batch process for E. coli RV308 clone expressing a dAb, originally developed for lab-scale conventional SS bioreactor, 
was transferred and scaled up to XDR-500 MO SUB. Mineral salt medium complemented with yeast extract in combination 
with 60% (w/v) glycerol substrate feed was used for cultivations. Process parameters critical for dAb expression were kept 
constant between technologies, while others were adapted to single-use technology (Table 1). Dissolved oxygen level was 
cascade controlled by stirrer speed, airflow, and oxygen enrichment of airflow in the single-use system.
Substrate feeding strategy was adapted to the SUB and three different rates were evaluated.
Medium and feed solutions were prepared in Xcellerex XDUO mixer bags and sterile filtered into the to single-use bioreactor. 
All cultures have been induced at an OD600nm of 80.
Improved process understanding during transition to SUB indicated substrate overfeeding in the SS bioreactor.  Evaluation of 
three reduced feed regimes showed that even applying as low as 60% of the original feed rate to XDR-500 MO was sufficient to 
maintain cell growth, as shown for XDR-Run 3 in Figure 1, and product formation was found to be at comparable levels to the 
original process. The reduced substrate feed also led to decreased oxygen consumption rate. 
Levels of expressed dAb achieved in XDR-500 MO after process transfer and scale-up were reproducible and comparable with the 
SS bioreactor (Fig 2) even without process optimization. Furthermore, it was shown that dAb concentration increased linearly after 
induction (Fig 3), indicating a straightforward strategy to improve product titer.
Critical process parameters like dissolved oxygen level, pH, and temperature were controlled efficiently within their targeted range 
under the entire cultivation. Temperature was maintained at 37˚C ± 0.1̊ C even when metabolic heat generation peaked at 38 000 
BTU/h. Instead of increasing headspace pressure, DO was maintained with oxygen enrichment, enabling cell growth to high cell 
densities (Fig 4).
Process economy
Fig 2. Comparison dAb expression levels obtained in single-use XDR-500 MO 
and stainless steel reactors. Product concentrations were determined after 
5 h induction time.
Fig 3. Effect of extended induction time on dAb expression.
Table 2. Comparison of process economy for dAb production between XDR-500 MO SUB and  SS bioreactor (scenarios for single and multiple 
product facilities were evaluated)
Table 1. Process transfer and scale-up strategy 
Fig 4. Parameter chart of a typical dAb cultivation in the single-use 
XDR-500 MO.
Fig 1. Cell growth in XDR-500 MO at studied feed rates. Cell growth even 
at lowest feed rate was comparable with stainless steel bioreactor.
Fig 5. Total production cost to number of batches produced annually 
in single-use and stainless steel facilities.
Conclusions
• XDR-500 MO allowed robust control of challenging 
process parameters (DO, pH, temperature).
• The model process successfully transferred and scaled 
up from SS bioreactor to SUB without the need for 
extensive modifications.
• Cell growth and dAb production level were comparable 
across technologies/scales even with the implemented 
changes.
• Higher production flexibility and facility utilization can 
be achieved with single-use systems.
• Single-use systems are viable alternatives to 
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Parameter Scenario 1 – Single product facility Scenario 2 – Multi product facility
Type of Bioreactor SS SUB SS SUB
Maximum number of batches 100 150 67 135
Relative cost comparison 1× 1.47× 1× 1.40×




















pH and DO set points DO control strategy
Medium and feed composition Medium and feed preparation procedures
Induction conditions Substrate feed profile
Temperature set point 
Experimental results
Comparison of process economy between single-use and 
conventional SS production facilities for dAb manufacturing 
revealed up to twice as high facility utilization when 
producing in a single-use system (Table 2).
According to our model, at 4–15 annual batches (e.g., for 
toxicology or early clinical phase studies), it is more cost-
effective to manufacture in a single-use facility compare 
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